SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gene therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (74)6/21/1999 11:51:00 PM
From: scaram(o)uche  Read Replies (2) of 319
 
taking a serious look..... the old MBIO is of interest from the Colorado connection, but I haven't heard anything about that program moving forward. I haven't looked hard. The Merck deal with GMED will be fun to watch, but I virtually know nothing more about their pre-merger stuff. The reason that I'm looking is the PEGylation work and "When
recombinant Del1 was evaluated in an in ovo chick chorioallantoic membrane assay, it was found to have potent angiogenic
activity. This angiogenic activity was inhibited by a monoclonal antibody directed against alphavbeta3, and an RAD mutant
Del1 protein was inactive."

But, overall, looks like a diffuse mishmash..... need to find an anchor..... what do you like most?

Thanks, I was watching it firm up too.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News